Hyperkalemia in heart failure: Foe or friend?

Amina Rakisheva MD, PhD1 | Maria Marketou MD, PhD2 | Anna Klimenko MD, PhD3 | Tatyana Troyanova-Shchutskaia MD4 | Panos Vardas MD, PhD5

1Department of Cardiology, Scientific Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
2Department of Cardiology, Heraklion University Hospital, Crete, Greece
3RUDN University, Moscow, Russian Federation
4Department of Cardiology, Scientific and Practical Center of Cardiology, Minsk, Belarus
5Department of Cardiology, Heart Sector, Hygeia Hospitals Group, Athens, Greece

Correspondence
Maria Marketou, Department of Cardiology, Heraklion University Hospital, Heraklion, Greece.
Email: maryemarke@yahoo.gr

Abstract
Hyperkalemia is a frequent and sometimes life-threatening condition that may be associated with arrhythmia and cardiac dysfunction in patients with heart failure (HF). High potassium levels in HF represent both a direct risk for cardiovascular complication and an indirect biomarker of the severity of the underlying disease, reflecting neurohormonal activation and renal dysfunction. Evaluating the prevalence and significance of hyperkalemia in HF patients is essential for optimizing the use of potassium sparing agents, such as the renin–angiotensin–aldosterone system inhibitors (RAASi) or angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists, which represent a well-established cornerstone and life-saving therapy. In this review we discuss recent findings and current concepts related to the epidemiology, pathological mechanisms and implications of hyperkalemia, as well as novel therapeutic approaches to counteract it in patients with HF. The balance between optimizing life-saving potassium sparing medication and minimizing hyperkalemia-associated risk is much needed in patients with HF. Although older potassium-binding agents are associated with serious adverse events, novel potassium-binding drugs are effective in lowering potassium levels and are generally well tolerated. Novel potassium-binding drugs, such as patiromer and sodium zirconium cyclosilicate, may help to optimize therapy in HF and achieve guideline-recommended doses. Hyperkalemia is common in HF patients and is associated with a poorer prognosis and an increased risk of cardiovascular complications: Conversely, “moderate” potassium levels go with a better prognosis, while the emergence of new drugs, potassium binders, could allow target doses of RAASi to be achieved.

KEYWORDS
angiotensin, heart failure

INTRODUCTION
Heart failure (HF) is a syndrome with high morbidity and mortality that has acquired pandemic dimensions, affecting more than 38 million people worldwide. In addition, the progressive nature of HF makes it a leading cause of hospitalization, due to the deleterious effects of sustained neurohormonal activation and comorbidities. Electrolytic disturbances, most usually of potassium levels, very often accompany...
HF, are a hindrance to the optimization of medication and impose a further burden on the patient. Since potassium plays a major role in cardiac excitability and arrhythmias, dyskalemia is an important clinical problem that is associated with significant life-threatening complications.\textsuperscript{3,4} Although the definition is not consistent always, hyperkalemia is generally defined as a serum potassium level \( >5.0 \) to \( 5.5 \) mEq/L and can be further classified as mild (5.6-6.0 mEq/L), moderate (6.1-7.0 mEq/L), and severe (>7.0 mEq/L). Potassium secretion is highly dependent on renin-angiotensin-aldosterone system (RAAS) activity and renal perfusion, as well as sodium availability to the distal nephron. Hyperkalemia represents both a direct risk for cardiovascular morbidity and a potential biomarker of adverse prognosis and disease severity. Patients with HF are at particularly high risk for hyperkalemia, which is likely to reflect some medical comorbidity, especially renal dysfunction. In addition, it is one of the most common factors that impede the optimum pharmaceutical approach to HF, leading to underuse of renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs), which are the drugs that offer the most help and have changed the outcomes of HF patients.\textsuperscript{5} Unfortunately, some additional independent risk factors, such as diabetes mellitus (DM), advanced age and renal insufficiency, that exacerbate all-cause and in-hospital mortality and hospitalizations in HF patients, also further increase the risk of hyperkalemia. At the opposite end of the scale is hypokalemia, which can also be observed in HF patients and can increase the risk of mortality, mainly via arrhythmogenic complications.\textsuperscript{6-8} Thus, both high and low potassium levels are unacceptable in HF patients. Data from the literature highlight the need for careful potassium monitoring, especially in the presence of comorbidities, with special emphasis being placed on patients with a low estimated glomerular filtration rate (eGFR).\textsuperscript{5}

This review aims to summarize the recent findings and the current concepts related to the epidemiology, pathological mechanisms, and implications of hyperkalemia, and to discuss novel therapeutic approaches in patients with HF. Although strategies of management are not evidence based, a deep investigation and understanding of these issues could form the basis for a better treatment of dyskalemia in those patients, and hence their optimum clinical approach.

2 | REGULATION OF POTASSIUM HOMEOSTASIS

Potassium is a very important electrolyte for the maintenance of the physiologic cell function. Approximately 2% of total-body K+ is in extracellular fluid, whereas 98% of K+ is in the intracellular compartment. Cellular Na+-K+-ATPase plays a key role in this homeostasis by pumping Na\textsuperscript{+} out of the cell and K\textsuperscript{+} into the cell and this process leads to a K\textsuperscript{+} gradient across the cell membrane which is vitally important for normal cellular function. The body has developed numerous mechanisms for maintaining serum K\textsuperscript{+} in a narrow range and kidney is the organ with the primary responsibility of this and adjustments in renal K\textsuperscript{+} excretion occur over several hours. Serum potassium homeostasis is usually preserved until GFR is reduced substantially.

There are several mechanisms regulating potassium secretion and potassium reabsorption. K\textsuperscript{+} is freely filtered across the glomerulus and then reabsorbed by the proximal tubule and thick ascending limb of the kidney. The shift in lumen potential from negative to positive in the proximal tubule provides a driving force for K\textsuperscript{+} reabsorption. In the thick ascending limb, K\textsuperscript{+} reabsorption is mediated mostly by the Na\textsuperscript{+}-K\textsuperscript{+}-2Cl\textsuperscript{-} cotransporter located on the apical membrane while a small proportion is reabsorbed through the paracellular pathway. Important factors for this regulation include luminal sodium delivery and flow rate, plasma potassium concentration, circulating aldosterone and arginine vasopressin, and acid-base status. Aldosterone, angiotensin II, distal delivery of Na\textsuperscript{+} and water are key factors in the renal excretion of K\textsuperscript{+}. Angiotensin II-mediated stimulation of aldosterone secretion from the adrenal gland control renal blood flow and GFR and therefore potassium balance. Decreased renal excretion of K\textsuperscript{+} can be due to a decreased distal delivery of Na\textsuperscript{+}, mineralocorticoid deficiency, and/or abnormal cortical collecting tubule function. In addition, catecholamines through β\textsubscript{2}-stimulation regulate extracellular K\textsuperscript{+} concentration. K\textsuperscript{+} homeostasis mechanisms are also modulated in the gut and ranges according to potassium intake through diet.

3 | INCIDENCE OF HYPERKALEMIA IN HF PATIENTS

In general, the incidence of hyperkalemia is 2% to 3%, but the latest data demonstrate a scatter up to 55% among hospitalized patients, reaching 73% in patients with CKD.\textsuperscript{9-12} Observational data from a large Scandinavian cohort indicate that hypokalemia occurred in approximately 14% of patients in the clinical setting, with 33% recurrence, while hyperkalemia was less frequent: 7% of patients with 35.7% recurrence.\textsuperscript{13} In a recent Danish population-based cohort study, almost four in 10 patients with HF developed hyperkalemia, and many patients have recurrent hyperkalemia episodes. Hyperkalemia risk was strongly associated with kidney function impairment and with severe clinical outcomes and death in HF.\textsuperscript{14} Even in well-selected populations with careful electrolyte monitoring, such as those in the PARADIGM-HF trial, the incidence of hyperkalemia with ACEi was 16% over a median follow-up time of 27 months.\textsuperscript{15} It has also been shown that hyperkalemia is present in 9% of patients admitted for acute HF.\textsuperscript{16} One study showed that 10% to 38% of hospitalized patients who received an ACEi developed hyperkalemia during hospitalization and 10% of patients prescribed an ACEi developed severe hyperkalemia within 1 year of follow-up.\textsuperscript{12,17,18} In another, which analyzed a large cohort of 19 194 patients with new-onset HF in the UK, 11% developed hyperkalemia during a 4-year follow-up.\textsuperscript{19} However, apart from the high incidence of hyperkalemia in patients who have HF with reduced ejection fraction (HFrEF), it is also common in HF with preserved ejection fraction (HfPEF). Indeed it may be even more common in HfPEF than in HFrEF, since this population is older, with a high burden of comorbidities and kidney failure. The TOPCAT trial, which examined the impact of treatment with
spironolactone on clinical outcomes in HFpEF, found an increased incidence of hyperkalemia in those patients. However, the TOPCAT findings showed that the cutoff of >5.0 mEq/L was not associated with an adverse prognosis, suggesting that the guidance provided in the trial to adjust study drug dosing only for sustained K+ values ≥5.5 mEq/L is reasonable in clinical practice. The European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT) has reported that the presence of hyperkalemia in chronic HF is 2.64%, reaching 4.44% in patients with acute HF. The discrepancies between the various studies are due not only to their different patient populations, but also to the different definitions of hyperkalemia used and the presence of the various risk factors mentioned above. Recently, Savarese et al. have shown that the risk of moderate or severe hyperkalemia was highest in HFpEF and HF with midrange ejection fraction, whereas risk of hypokalemia was highest in HFpEF. HF severity, low hemoglobin, COPD, baseline high and low potassium, and low eGFR were relevant predictors of dysK occurrence.

The extent to which hyperkalemia is implicated in the morbidity and mortality of HF patients is difficult to assess, since it may be asymptomatic and may only be discovered through routine blood screening, or as a consequence of the condition leading to hospitalization (eg, infection, dehydration, or deteriorating kidney function), rather than causing the hospitalization itself. Patients at high risk for hyperkalemia are often those with disease states such as HF and CKD, who also stand to benefit most from RAASi. However, most clinical trials have excluded patients with advanced CKD, who are those at the highest risk for hyperkalemia; consequently, we lack evidence regarding the therapeutic management and long-term outcomes in this population.

4 | PROGNOSTIC IMPLICATIONS OF HYPERKALEMIA IN HF

Systemic hyperkalemia results in a shortening of the membrane action potential and altered conduction velocity. Initially, there is a decrease in the effective refractory period, but as hyperkalemia worsens increased K+ channel conductances can induce post-repolarization refractoriness and prolongation of the effective refractory period. The electrocardiogram first demonstrates peaked T waves resulting from global action potential shortening. Subsequently, the P wave broadens and decreases in amplitude, eventually disappearing, and the QRS widens. Severe hyperkalemia (K+ >7.0 mmol/L) can lead to heart block, asystole, and ventricular tachycardia or fibrillation (VT/VF). Similarly, interstitial hyperkalemia during acute ischemia has all of the electrophysiological actions described above, which are exacerbated by concomitant hypoxia or acidosis. Interstitial hyperkalemia also promotes early repolarization in the ischemic subepicardium, inducing phase 2 re-entry and VT/VF analogous to Brugada syndrome. Apart from cardiac arrhythmias, potassium disorders can also result in muscle cramps, muscle weakness, rhabdomyolysis, and myoglobinuria.

Although serum potassium up to 5.5 mEq/L appears relatively safe in HF, many studies have pointed out the association between high serum potassium and adverse clinical outcomes in HF patients. It has been reported that the rate of in-hospital death associated with hyperkalemia in HF patients reaches 0.39 per 1000 patients. A Spanish registry has shown that, in patients hospitalized for decompensated HF, admission hyperkalemia predicts a higher midterm risk for HF readmission and mortality, probably related to the significant higher risk of readmission.

On the MEESSI-AHF scale, hyperkalemia is a variable associated with a greater risk of 30-day mortality. Conversely, correction of hyperkalemia to normokalemia leads to a lower risk of all-cause mortality during follow-up. On the other hand, hyperkalemia has been associated with both increased and decreased mortality risk in various trials. This largely depends on the clinical substrate, that is, whether hyperkalemia is coming from renal dysfunction or due to potassium sparing drugs. The latter is associated with improved prognosis in specific populations and avoidance of hypokalemia. This may explain why a high potassium level may be protective especially in the long term. In contrast, critically ill patients and in patients with chronic kidney disease, high potassium levels are associated with high rates of arrhythmias and cardiac arrest. Notwithstanding, published studies demonstrating an association of mortality with hyperkalemia are largely limited to retrospective analyses and have no design to provide evidence of causation.

Hoss et al. suggested that spironolactone and loop diuretic therapy appear to be safe in patients with high-normal potassium levels, HF and reduced renal function and are associated with an improved outcome.

In a large, geographically diverse United States population receiving medical care, 27.6% had a potassium level <4.0 mEq/L while 5.7% had ≥5.0 mEq/L. A U-shaped association was revealed between serum potassium and mortality, with the lowest all-cause mortality seen in controls with potassium values between 4.0 and <5.0 mEq/L. However, the effect on mortality was more severe for hypokalemia than for hyperkalemia, since the investigators observed 45.5% mortality with moderate-to-severe hypokalemia and a 35.7% death rate associated with hyperkalemia in those with HF.

After publication of the RALES trial, hospitalization for hyperkalemia in the Canadian health system rose significantly, and this was associated with an increased risk of death among those patients. A decline in eGFR exceeding 20% or 30% was independently associated with a more frequent occurrence of all clinical adverse events. In an EPHEBUS post hoc analysis, four independent baseline predictors of hyperkalemia (defined as ≥6.0 mEq/L) were identified: baseline potassium greater than the median (4.3 mEq/L), baseline eGFR ≥60 mL/min per 1.73 m², a history of diabetes mellitus, and previous use of antiarrhythmic agents. In the BIOSAT-CHF cohort, at baseline, hypokalemia (<3.5 mEq/L) was present in 6.9% and hyperkalemia (≥5.0 mEq/L) in 8.0%. On the other hand, discontinuation of RAASi therapy exhibited a J-shaped trend in association with serum potassium. Basnet et al., in a study of 2660 609 patients who were discharged with a diagnosis of HF, reported that patients with hypokalemia during hospitalization had a greater mortality risk than those with hyperkalemia. Low serum potassium is known to increase the
transmembrane resting potential of myocardial cells, resulting in increased excitability and leading to a higher risk of atrial fibrillation, Q-T interval prolongation, torsade des pointes, ventricular arrhythmias, ventricular fibrillation, and sudden cardiac death. This might explain the fact that hypokalemia in HF has been associated with an increased risk of mortality, with hazard ratios ranging from 1.2 to 2.3.\textsuperscript{7,8,35}

Notably, the Swedish HF registry, using real world data, showed that during the 1-year follow-up from baseline, 1.45 deaths per 1000 patient-years occurred after hyperkalemia compared to 0.33 deaths that occurred in periods without or preceding hyperkalemia.\textsuperscript{22} The results were similar across the spectrum of HF. The risk of moderate or severe hyperkalemia or severe hypokalemia was the same and had the same prognostic impact regardless HF category. In contrast, the same study found that the incidence of hyperkalemia was not associated with increased hospitalizations.\textsuperscript{22} In addition, post hoc results from the TOPCAT-Americas study, a large clinical trial with HFpEF patients indicate that among patients with eGFRs of <45 mL/min/1.73 m\textsuperscript{2}, for every 100 patients treated with spironolactone, they would expect to prevent nine occurrences of the primary composite outcome but provoke 27 drug discontinuations because of hyperkalemia.\textsuperscript{36}

5 | PROTECTIVE EFFECTS OF POTASSIUM

Diets high in potassium have been associated with a lower incidence of hypertension and heart failure.\textsuperscript{37} Experimental data show that high potassium protects against hypertensive and sodium-induced endothelial dysfunction, independently of blood pressure.\textsuperscript{38-40} In animal models, increasing plasma potassium improves endothelial function and arterial stiffness, reducing the rate of thrombosis on endothelial lesions.\textsuperscript{39,40} Notably, high potassium levels have been shown to have protective effects against stroke and kidney disease in hypertensive rats.\textsuperscript{41}

In general terms, serum potassium 4 to 4.9 mEq/L is optimal and 5 to 5.5 mEq/L appears relatively safe in HF.\textsuperscript{7} In a large cohort of patients with acute HF, patients with higher serum potassium were found to have a better diuretic response and low potassium was one of the strongest predictors of a poor diuretic response.\textsuperscript{16} It also appears that eGFR is lower in HF patients with higher potassium levels, which probably means that high potassium levels reflect worse renal function and may be a risk marker rather than a risk factor.\textsuperscript{16}

In the EPHEBUS trial, eplerenone also reduced the risk of hypokalemia, which was twice as large as the risk of serious hyperkalemia.\textsuperscript{32} Important findings from EMPHASIS-HF suggest that the favorable effects of eplerenone on all-cause death were independent of the incidence of hyperkalemia or worsening renal function.\textsuperscript{32,43} On the other hand, a sub-study from the RALES trial in chronic HF found that an increase in potassium levels after spironolactone treatment was not associated with an increase in mortality.\textsuperscript{31} In the RALES trial, the benefit of spironolactone was maintained in the setting of moderate hyperkalemia, and clinical outcomes with spironolactone were superior to those with placebo when potassium levels remained <6.0 mEq/L.\textsuperscript{31} In this trial, 13.5% and 40% of participants exhibited hyperkalemia when treated with 25 and 50 mg daily of spironolactone, indicating that hyperkalemia in HF is not always an ominous sign. Results from a recent, large, network-wide analysis suggested that there was no difference in outcomes between patients with normal or mildly elevated potassium levels.\textsuperscript{31} Notably, serious hyperkalemia occurred in only 2% and 1% of patients in the spironolactone and placebo arms, respectively.\textsuperscript{31}

6 | HYPERKALEMIA IN LARGE CLINICAL TRIALS

The cornerstone of HF treatment is RAASi and MRAs and current HF guidelines\textsuperscript{5} recommend them for patients who have HFrEF unless they are contraindicated or not tolerated. There is evidence to show that these drugs can increase potassium levels from <2% to 5%-10%, depending on the baseline characteristics.\textsuperscript{3,30,44} The smallest increase is observed among hypertensive patients without any risk factors, while the greatest is among patients with HF and CKD. Thus, HF treatment management always takes this kind of interaction into account and often limits the prescription of RAASi and its target dose titration. Apparently, most of them involved MRAs, whether spironolactone or eplerenone. Thus, RALES, EPHEBUS, and EMPHASIS-HF are three large randomized studies of MRAs in patients with HFrEF.\textsuperscript{30-32,45} The ATHENA-HF trial was also conducted to assess MRAs among patients with acute HF, regardless of ejection fraction.\textsuperscript{46} Another study in patients with HFpEF and NYHA II-IV, PARADIGM-HF, compared sacubitril/valsartan with enalapril.\textsuperscript{15} TOPCAT was the only study where HFpEF was a main inclusion criterion.\textsuperscript{47} A safety analysis of the abovementioned studies is presented in Table 1. In the RALES, EPHEBUS, and TOPCAT studies hyperkalemia was identified when potassium level was >5.0 mmol/L and only the EMPHASIS-HF trial identified hyperkalemia as a potassium level >4.5 mmol/L. Furthermore, the following stages of hyperkalemia were defined in this trial: mild (4.5 mmol/L), moderate (5.0 mmol/L), and severe (≥5.50 mmol/L).\textsuperscript{30,31,41,46} Mineralocorticoids contribute to potassium loss and sodium absorption, while their antagonists have the reverse action and cause potassium absorption. Thus, the serum potassium level was higher among patients in the treatment group of MRA trials in comparison with placebo controls. However, MRAs improve prognosis despite leading to increased rates of hyperkalemia or hypokalemia.\textsuperscript{30} Apart from primary cardiovascular prevention of MRAs an additional advantage is the maintenance of potassium levels within normal range and the protection from hypokalemia.

Although ATHENA-HF was also an MRA trial, its design was different and focused on an evaluation of the standard therapy with spironolactone of 25 mg, or a higher dose of 100 mg, vs placebo.\textsuperscript{49} There were only one event of high potassium level in the standard treatment arm and no hyperkalemia event in the group with a high spironolactone dose. The other study, PARADIGM-HF, was conducted to compare two disease-modifying drugs, sacubitril/valsartan and
enalapril; since both of them contribute to hyperkalemia, serum potassium levels >5.5 mmol/L were registered in both groups. Nevertheless, a trend for higher potassium level (≥6.0 mmol/L) was identified in the enalapril arm (4.3% vs 5.6%; R = .007). Hypokalemia was frequently identified among patients in the placebo group in the RALES, EMPHASIS-HF, and EPHESUS trials, and was associated with increased mortality, especially when the serum potassium level was <3.5 mmol/L. The TOPCAT trial compared spironolactone and placebo in patients with HFpEF, found an increase in potassium levels in the treatment arm and a significant decrease in the placebo arm. There were no serious adverse effects in either group. Notably, a potassium level above 4.8 mmol/L has been related with increased mortality on clinical trials with HF patients and thus has been recommended by some researchers as the upper normal limit on HF.

| Study name       | Criteria of hyperkalemia used in large trials | Number of patients with hyperkalemia | Number of patients with hypokalemia |
|------------------|---------------------------------------------|-------------------------------------|-------------------------------------|
| RALES<sup>31</sup> | Mild K⁺ 5.0–5.4 mmol/L
Moderate K⁺ 5.5 to 5.9 mmol/L
Severe K⁺ ≥ 6.0 mmol/L | 156 patients in spironolactone group and 47 in placebo | 53 patients in spironolactone group and 136 in placebo |
| EPHESUS<sup>32</sup> | K⁺ >5.0 mmol/L | 113 (3.4%) in eplerenone group and 66 (2.0%) placebo group | 15 (0.5%) in eplerenone group and 49 (1.5%) placebo group |
| EMPHASIS-HF<sup>43</sup> | Hyperkalemia variably defined as K⁺ >4.5, >5, or >5.5 mmol/L | 158 patients (11.8%) in the eplerenone group and 96 patients (7.2%) in the placebo group (P < .001). | K <3.5 mmol/L was reported in 100 patients (7.5%) in the eplerenone group and 148 (11.0%) in the placebo group (P = .002) |
| TOPCAT<sup>20</sup> | K⁺ ≥ 5.0 mmol/L | 18.7% in the spironolactone group vs 9.1% in the placebo group | 16.2% in the spironolactone group vs 22.9% in the placebo. |
| ATHENA-HF<sup>46</sup> | Moderate >5.5 mmol/L;
Severe >6.0 mmol/L | Only one patient in the group receiving usual care and 0 in the group taking high-dose spironolactone experienced serum potassium levels between 5.5 and 5.9 mEq/L, and no one had a potassium concentration of >6.0 mEq/L during the 96 h of study treatment. Serious adverse events by 30 days were reported in 84 patients (47%) in the group receiving usual care and 79 patients (43%) taking high-dose spironolactone (P = .47). |
| PARADIGM-HF<sup>15</sup> | K⁺ >5.5 mmol/L | 674 (16.1%) in sacubitril/valsartan vs 727 (17.3%) in enalapril; P = .15 | 139 (3.31%) in sacubitril/valsartan vs 107 (2.53%) in enalapril |
|               | K⁺ ≥ 6.0 mmol/L | 181 (4.3%) in sacubitril/valsartan vs 236 (5.6%) in enalapril; P = .007 |

### 7 | HYPERKALEMIA AS AN OBSTACLE TO OPTIMUM HF TREATMENT

Drug-induced hyperkalemia is one of the most common causes of hyperkalemia in HF. Unfortunately, this fear results in clinicians' inertia who very often discontinue or down-titrate medications that induce it. On the other hand, disease modifying drugs statistically reduce the risk of mortality in HF patients, and their adverse effect, such as hyperkalemia, contribute to an improvement of prognosis only when serum potassium levels show moderate elevation. Meanwhile, the development of hypokalemia worsens prognosis and increases mortality. The same effect was observed if the potassium level was over ≥6.0 mmol/L. Although mild hyperkalemia is not a clinical problem, given the risk of development of more severe hyperkalemia, serum potassium levels should be closely monitored in high-risk patients. While in the era of trials such as RALES and EMPHASIS-HF,<sup>30,42</sup> the rate of discontinuation is low in clinical practice, among new users of MRA therapy rates of discontinuation in the first year are high even with mild hyperkalemia. Of the patients who experience hyperkalemia, almost half discontinue the drug, with only a small percentage trying a reduced dose, and of those who discontinue the drug because of hyperkalemia, few restart.<sup>48</sup> In a large retrospective clinical trial in patients with new onset HF, serum potassium concentrations outside 4.0 to 5.0 mmol/L were associated not only with elevated mortality risk, but also with increased likelihood of RAASi discontinuation.<sup>49</sup>
Although the management of hyperkalemia in these patient populations may include reduction or discontinuation of RAASi, this may have a negative impact on outcomes. Adverse cardio-renal outcomes have been observed to increase with RAASi dose reduction or discontinuation, particularly in cohorts with CKD and HF. Therefore, optimizing the therapeutic dosage of RAASi is encouraged, despite any difficulties in managing hyperkalemia. Due to the high prevalence of comorbidities among patients with HF, there is a risk that target doses of the disease-modifying drugs cannot be achieved, reducing the effectiveness of the therapy.

Although the problem of hyperkalemia in these patients appears significant, one if its clear causes are the lack of sufficient control of potassium levels in primary care, which leads to the hyperkalemia rates described above, together with their complications. Nilsson et al. examined patients starting MRA therapy between 2007 and 2010 in Sweden and found that only 24% were adequately monitored at the recommended intervals. The prompt recognition of hyperkalemia usually leads to its treatment, improving the rates of optimum treatment in HF patients.

In general, HF patients with renal dysfunction, high potassium levels (>5.0 mEq/L) or bilateral renal stenosis might need a rechecking of potassium levels within 1 to 2 weeks after the initiation of RAASi and then every 3 to 5 months, while treatment may be stopped or the dose reduced when potassium is >5.5 mEq/L. Regarding MRAs in these patients, potassium is checked after 1 week, then 4, and then every 3 months; again, treatment is stopped or tapered when the potassium level reaches >5.5 mEq/L.

In every case, we should try to restart treatment. HF treatment guidelines do not encourage MRAs use in patients with an eGFR <30 mL/min per 1.73 m² or serum potassium levels >5.0 mmol/L. In addition, it is important to instigate dietary counseling regarding potassium and reappraise concomitant medications (e.g., potassium supplements, nonsteroidal anti-inflammatory drugs, etc.) in those patients.

8 | HYPERKALEMIA MANAGEMENT: FOCUS ON NEW TREATMENTS

The treatment of chronic hyperkalemia can be difficult and may be life-threatening if left untreated. Potassium binders such as sodium polystyrene sulfonate is mainly used in patients with CKD and hyperkalemia. This substance is only suitable for short-term treatment since its use is associated with hypernatremia, volume overload and gastrointestinal complications. A suggested management of chronic hyperkalemia in HF patients is presented in Figure 1. However, their use is associated with adverse effects, their efficacy is uncertain and their effects are transient. In this regard, the introduction of patiromer, acting at the level of the gastrointestinal tract, in particular in the colon lumen, is relevant, may decrease serum potassium levels and enable treatment with RAASi and MRAs in significantly higher doses. Patiromer for oral suspension is a non-absorbed, sodium-free potassium binding polymer that exchanges calcium for potassium in the gastrointestinal tract. Patiromer beads are insoluble, have an average particle size of ≈100 μm and so are too large to be absorbed, excreted ≈24 to 48 h after intake and bind potassium predominantly in the lumen of the colon and this increases fecal potassium excretion, reducing levels of free potassium. The mean reduction of serum potassium levels by patiromer in large clinical trials was in the range 0.45 to 1 mmol/L.

Zirconium cyclosilicate (SCZ, former ZS-9)—an inorganic cation that allows a thermodynamically favorable catching of potassium ions—represents another significant pharmacologic advancements in the treatment of hyperkalemia. More specifically SCZ is an oral, nonabsorbed, high-capacity cation-binding compound that selectively exchanges K⁺ for hydrogen and sodium ions throughout the gastrointestinal tract and has rapid onset of action. A single treatment with SCZ may reduce serum K⁺ levels at 1 h after the initial dose, results in a continued and sustained reduction in serum K⁺ levels for up to 48 h after the initial dose and has a favorable safety profile. The mean...
| Study name                  | Number of patients | Agent                        | Mean follow-up | Inclusion criteria                                                                 | Results                                                                                                                                 |
|----------------------------|--------------------|------------------------------|----------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| AMETHYST-DN<sup>54</sup>   | 324                | Patiromer (4.2 g, 8.4 g or 12.6 g twice daily [mild hyperkalemia] or 8.4 g, 12.6 g, or 16.8 g twice daily [moderate hyperkalemia]). | 52 weeks       | eGFR:15 to < 60 mL/min/1.73 m<sup>2</sup> K+ >5.0 mEq/L Type 2 diabetes Receiving an ACEi, an ARB, or both for ≥28 days | Mild hyperkalemia: Mean K+ reduction −0.35 mEq/L for the 4.2 g, −0.51 mEq/L for the 8.4 g, −0.55 mEq/L for the 12.6 g Moderate hyperkalemia: the reduction was −0.87 mEq/L for the 8.4 g, −0.97 mEq/L for the 12.6 g, and −0.92 mEq/L for the 16.8 g hypokalemia (<3.5 mEq/L) occurred in 5.6% of patients |
| OPAL-HK<sup>55</sup>       | 243                | Patiromer (8.4 or 16.8 g)    | 4 weeks        | 3rd or 4th stage of CKD eGFR −15 to 60 mL/min/1.73 m<sup>2</sup>; K+ 5.1 to 6.5 mmol/L stable dose of one or more RAASi for ≥28 days | Reduction of K+ levels −1.01 mmol/L vs placebo (P < .001)                                                                                                                                       |
| PEARL-HF<sup>56</sup>      | 120                | Patiromer (15 g b.i.d. or placebo) | 4 weeks        | CHF a serum K+ 4.3-5.1 mEq/L In addition: (i) CKD [with (eGFR) of 60 mL/min] and were receiving one or more HF therapies (ACE-I, ARBs, beta-blockers); or (ii) a documented history of hyper-kalaemia that led to discontinuation of therapy with an AA, ACE-I, ARB, or beta-blocker within 6 months prior to the baseline visit. | Reduction of K+ levels −0.45 mmol/L vs placebo (P < .001)                                                                                                                                       |
| TOURMALINE<sup>57</sup>    | 112                | Patiromer (8.4 g)            | 3 or 4 weeks   | K+ >5.0 mmol/L; 67 receiving RAASI                                                 | From baseline to week 4, the mean (SE) change in serum potassium was −0.67 (0.08) mEq/L in patients taking RAASI and −0.56 (0.10) mEq/L in patients not taking RAASI |
| HARMONIZEHF subgroup<sup>58</sup> | 94       | Sodium zirconium cyclosilicate (5, 10, or 15 g or placebo) | 28 days       | K+ >5.0 mmol/L; 60 receiving RAASI                                                 | Treatment maintained a lower potassium level (4.7 mmol/L, 4.5 mmol/L, and 4.4 mmol/L, respectively) than the placebo group and greater proportions of patients (83%, 89%, and 92%, respectively) maintained normokalaemia than placebo overall study population. |
| HARMONIZE-Global Study<sup>59</sup> | 248     | Sodium zirconium cyclosilicate (three-daily 10 g during a 48 h correction phase, patients achieving normokalaemia were randomized to once-daily 5 g, 10 g, or placebo) | 28 days       | K+ >5.1 mmol/L                                                                   |                                                                                                                                                                                                 |
| Roger et al.<sup>60</sup>  | 751                | Sodium zirconium cyclosilicate 10 g three times daily | 365 days  | K+ ≥5.1 mmol/L                                                                   | 100% and 95% with baseline eGFR <30 and ≥30 mL/min/1.73 m<sup>2</sup> achieved normokalaemia                                                                                                   |
| ZS-005<sup>51</sup>        | 751                | Sodium zirconium cyclosilicate 10 g three times daily for 24 to 72 h | 365 days  | K+ ≥5.1 mmol/L                                                                   | mean serum potassium values ≤5.1 and ≤5.5 mmol/L were achieved by 99% of participants                                                                                                        |

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
reduction of serum potassium levels by SCZ in large clinical trials was in the range 0.3 to 1.1 mmol/L.52

Table 2 summarizes the main studies whose aim was to evaluate the effect of potassium binding agents. An important inclusion crite-
rion of the AMETHYST-DN phase II study and the OPAL-HK phase III study was the presence of a serum potassium level above 5.0 mEq/L, CKD and RAASi use.54,55 Another patiromer study, PEARL-HF, was conducted for patients with documented HF and a potassium level of 4.3 to 5.1 mEq/L.56 Additional inclusion criteria were either a reduc-
tion of eGFR to ≤60 mL/min/1.73 m² while taking RAASI, or docu-
mented hyperkalemia that led to the cancellation of RAASI.

Both AMETHYST-DN and OPAL-HK showed reductions of serum potassium level throughout the study, regardless of whether patients had chronic heart failure, or advanced CKD, DM, or hypertension.54,55 The treatment period of PEARL-HF showed a lower incidence of hyperkalemia in the patiromer group compared with the placebo group (7% vs 25%, respectively).56 Contrariwise, more patiromer-
treated patients developed hypokalemia, with a K⁺ value <3.5 mEq/L (6% vs 0%, respectively) and significantly more had a K⁺ value <4.0 mEq/L compared with the placebo group (47% and 10%, respec-
tively). That led to an increase in the spironolactone dose in patients treated with patiromer compared with placebo patients (P = .019). In another open label study that included patients with baseline K⁺ < 5.0 mEq/L, patiromer was effective and generally well-tolerated for hyperkalemia treatment, whether or not patients were taking RAAS inhibitors.57

The results from using SCZ were encouraging: the HARMONIZE trial showed that all three doses of SCZ were effective in lowering and maintaining normal potassium levels, including patients receiving RAASI therapy, who showed similar safety profiles.58 In HARMONIZE-Global study, normokalemia achieved in a geographically and ethnically diverse population of outpatients with hyperkalemia.59 The most commonly reported AEs were oedema and constipation.59 SZC corrects hyper-
kalemia and maintains normokalemia among outpatients regardless of the CKD stage.60,61

Unfortunately, these agents cannot be used as emergency treatment while the short duration of the above studies is a limitation in the management of chronic hyperkalemia. Although outcome studies are lacking, the use of potassium binders could play an important role in reaching target doses of RAASI by preventing the development of significant hyperkalemia. However, this hypothesis requires further research on combination treatment with potassium binders before guidelines can recommend their use in therapy.

9 | CONCLUSIONS

Hyperkalemia is common in HF patients and is associated with a poorer prognosis and an increased risk of cardiovascular complica-
tions: this undoubtedly presents hyperkalemia as our “foe.” Contrariwise, “moderate” potassium levels go with a better prognosis, while the emergence of new drugs, potassium binders, could allow target doses of RAASI to be achieved, giving us an opportunity to think of hyperkalemia as a “friend.”

Although, important clinical trials52,42,43 in HF indicated that a potassium level of 5.0 to 5.5 mmol/L, according to the study design, does not offset the therapeutic benefits of HF treatment. Although, potassium levels >6.0 mEq/L have been associated with bradycardia, asystole, and sudden death, the exact modes of death related to hyperkalemia, is not clearly described in the large trials. Considering the risk of RAASI discontinuation,49 serum potassium concentrations between 4.0 and 5.0 mmol/L may be an ideal level. Dyskalemia incidence and related outcomes across epidemiological studies—specially in HFpEF is at present problematic and further studies are required to provide confidence as to the exact level of serum potassium below and above the normal range, which should be of concern and should trigger intervention. The balance between optimizing life-saving potassium sparing medication and minimizing hyperkalemia-associated risk is much needed in patients with HF.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID

Amina Rakisheva https://orcid.org/0000-0001-9842-962X
Maria Marketou https://orcid.org/0000-0003-1888-3430

REFERENCES

1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368-378.
2. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14:30-38.
3. Rosano GCM, Tamargo J, Kjeldsen KP, et al. Expert consensus docu-
ment on the management of hyperkalemia in patients with cardiovas-
cular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2018;4:180-188.
4. Lopez Vilella R, Morillas Climent H, et al. Hyperkalemia in heart failure patients: current challenges and future prospects. Res Rep Clin Cardiol. 2016;7:1-8.
5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart fail-
ure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016:18:891-975.
6. Bielecka-Dabrowa A, Mikhailidis DP, Jones L, et al. The meaning of hypokalemia in heart failure. Int J Cardiol. 2018:158:12-17.
7. Ahmed A, Zannad F, Love TE, et al. A propensity-match study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2008;29:1343-1343.
8. Alper AB, Campbell RC, Anker SD, et al. A propensity-match study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009;137:1-8.
9. Paice B, Gray JM, McBride D, Donnelly T, Lawson DH. Hyperkalemia in patients in hospital. Br Med J. 1983;286:1189-1192.
10. Moore ML, Bailey RR. Hyperkalemia in patients in hospital. N Z Med J. 1989;102:557-558.
11. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med*. 2009;169:1156-1162.

12. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. *Arch Intern Med*. 1998;158:917-924.

13. Nilsson E, Gasparini A, Arnlov J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. *Int J Cardiol*. 2017;245:277-284.

14. Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes—a Danish Population-Based Cohort Study. *J Am Heart Assoc*. 2018;7:e008912.

15. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371:993-1004.

16. Tromp J, TerMaaten JM, Damman K, et al. Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials). *Am J Cardiol*. 2017;119:290-296.

17. Ahuja TS, Freeman D Jr, Mahnken JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. *Am J Nephrol*. 2000;20:268-272.

18. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? *Arch Intern Med*. 1998;158:26-32.

19. Michel A, Martin-Perez M, Ruigomez A, et al. Risk factors for hyperkalemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. *Eur J Heart Fail*. 2015;17:205-213.

20. Desai AS, Liu J, Pfeffer MA, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. *J Card Fail*. 2018;24:313-320.

21. Crespo-Leiro MG, Anker SD, Magnani AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail*. 2016;18:613-625.

22. Savarese G, Xu H, Trevisan M, et al. Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. *JACC Heart Fail*. 2019;7:65-76.

23. Antzelevitch C, Yan GX. J-wave syndromes: Brugada and early repolarization syndromes. *Heart Rhythm*. 2015;12:1852-1866.

24. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med*. 2014;351:543-551.

25. Formiga F, Chivite D, Corbella X, et al. Influence of potassium levels on one-year outcomes in elderly patients with acute heart failure. *Eur J Intern Med*. 2019;60:24-30.

26. Miro O, Rossello X, Gil V, Martin-Sanchez FJ, et al. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. *Ann Intern Med*. 2017;167:698-705.

27. Aldahl M, Jensen AC, Davidsen L, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. *Eur Heart J*. 2017;38:2890-2896.

28. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. *Am J Nephrol*. 2017;46:2129-221.

29. Hoss S, Elizur Y, Luria D, Keren A, Lotan C, Gotman I. Serum potassium levels and outcome in patients with chronic heart failure. *Am J Cardiol*. 2016;118:1868-1874.

30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999;341:709-717.

31. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). *J Am Coll Cardiol*. 2012;60:2082-2089.

32. Pitt B, Williams G, Remme W, et al. The EPHESES trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. *Cardiovasc Drugs Ther*. 2001;15:79-87.

33. Beusekamp JC, Tromp J, van der Wal HH, et al. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. *Eur J Heart Fail*. 2018;20:923-930.

34. Basnet S, Dhiatal R, Tharu B, et al. Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample. *J Community Hosp Intern Med Perspect*. 2019;12(9):103-107.

35. Nunez J, Baye-Genus A, Zannad F, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. *Circulation*. 2018;137:1320-1330.

36. Beldhuis IE, Myhre PL, Claggett B, et al. Efficacy and safety of spironolactone in patients with HFrEF and chronic kidney disease. *J Am Coll Cardiol Heart Fail*. 2018;7:25-32.

37. Sugimoto T, Tobian L, Ganguli MC. High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. *Hypertension*. 1988;11:579-585.

38. Raj L, Luscher TF, Vanhoutte PM. High potassium diet augments endothelial-dependent relaxations in the Dahl rat. *Hypertension*. 1998;12:562-567.

39. Young DB, Lin H, McCabe RD. Potassium's cardiovascular protective mechanisms. *Am Physiol*. 1993;268:R825-R837.

40. Sudhir K, Kurtz TW, Yock PG, Connolly AJ, Morris RC Jr. Potassium preserves endothelial function and enhances aortic compliance in Dahl rats. *Hypertension*. 1993;22:315-322.

41. Tobian L. High-potassium diets markedly protect against stroke deaths and kidney disease in hypertensive rats, an echo from prehistoric days. *J Hypertens Suppl*. 1986;4:567-576.

42. Rossignal P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Circ Heart Fail*. 2014;7:51-58.

43. Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). *J Am Coll Cardiol*. 2013;62:1585-1593.

44. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. *Clin J Am Soc Nephrol*. 2010;5:531-538.

45. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*. 2011;364:11-21.

46. Butler J, Anstrom KJ, Felker GM, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). *J Am Coll Cardiol*. 2012;60:2082-2089.
49. Linde C, Qin L, Bakhai A, et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. *ESC Heart Fail*. 2019;6:280-290.

50. Epstein M, Reaven NL, Funk SE, McGaughey K, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care*. 2015;21(11 suppl):S212-S220.

51. Nilsson E, de Peco P, Trevisan M, et al. A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. *Eur Heart J Qual Care Clin Outcomes*. 2018;4:267-273.

52. Nassif ME, Kosiborod M. New frontiers for management of hyperkalaemia: the emergence of novel agents. *Eur Heart J Suppl*. 2019;21: A34-A40.

53. Amin AN, Menoyo J, Singh B, Kim CS. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥5.5 mmol/L: pooled analysis from two phase 3 trials. *BMC Nephrol*. 2019;20:440.

54. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalaemia and diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial. *JAMA*. 2015;314:151-161.

55. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalaemia receiving RAAS inhibitors. *N Engl J Med*. 2015;372:211-221.

56. Buysse JM, Huang IZ, PB. PEARL-HF prevention of hyperkalaemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. *Future Cardiol*. 2912:8:17-28.

57. Kloner RA, Gross C, Yuan J, Conrad A, Pergola PE. Effect of patiromer in hyperkalemic patients taking and not taking RAAS inhibitors. *J Cardiovasc Pharmacol Ther*. 2018;23:524-531.

58. Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. *Eur J Heart Fail*. 2015;17:1050-1056.

59. Zannad F, Hsu BG, Maeda Y, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. *ESC Heart Fail*. 2020;7:54-64.

60. Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. *Nephrol Dial Transplant*. 2020. https://doi.org/10.1093/ndt/gfz285.

61. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month Phase 3 study. *Clin J Am Soc Nephrol*. 2019;14:798-809.

How to cite this article: Rakisheva A, Marketou M, Klimenko A, Troyanova-Shchutskaia T, Vardas P. Hyperkalaemia in heart failure: Foe or friend? *Clin Cardiol*. 2020;43:666–675. https://doi.org/10.1002/clc.23392